araag2/HINT huggingface dataset:
Clinical trial NCT01225731 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult participants (≥18 years of age) with a diagnosis of moderate-to-severe chronic
             plaque psoriasis (defined by ≥10% body surface area [BSA] involvement, "moderate" or
             greater score on the Physician's Global Assessment [PGA] scale, and PASI score ≥12 at
             Baseline)

          -  Participants must have a diagnosis of predominantly plaque psoriasis for ≥6 months (as
             determined by interview and confirmation of diagnosis through physical examination by
             investigator) and be considered candidates for phototherapy or systemic therapy.
             Participants with psoriatic arthritis may be included in the study

        Exclusion Criteria:

          -  Nonplaque forms of psoriasis specifically erythrodermic psoriasis, predominantly
             pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new
             onset guttate psoriasis

          -  Participants who will require oral or injectable corticosteroids during the trial

          -  Presence of any infection requiring treatment with systemic antibiotics within 2 weeks
             prior to Screening, or serious infection (eg, pneumonia, cellulitis, bone or joint
             infections) requiring hospitalization or treatment with intravenous antibiotics within
             8 weeks prior to Screening

          -  Participants with evidence of active or untreated latent tuberculosis (TB) according
             to Screening criteria specified in the protocol. (Prophylactic treatment for latent TB
             as per local guidelines must be initiated at least 4 weeks prior to treatment with
             study medication)

          -  Previous exposure to any agents targeting interleukin-12 (IL-12) and/or Interleukin-23
             (IL-23)

          -  Participants with prior exposure to two or more tumor necrosis factor (TNF)
             antagonists with discontinuation due to lack of efficacy.
Clinical trial NCT01513317 (phase 2, status: terminated)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: siltuximab, placebo, best supportive care (bsc)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was stopped after the interim analysis based on lack of sufficient efficacy. there
    were no safety concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of myelodysplastic syndrome (MDS), according to World Heath
             Organization or the French-American-British Cooperative Group pathologic
             classification, with an International Prognostic Scoring System score 0, 0.5, or 1.0,
             indicating Low- or INT-1-risk disease.

          -  Documented RBC transfusion of at least 2 units of RBC for the treatment of the anemia
             of MDS in the 8 weeks preceding the start of the Screening Period.

          -  Adequate iron stores, demonstrated by either the presence of stainable iron in the
             bone marrow or a serum ferritin of > 100 ng/mL.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.

          -  Symptomatic anemia (defined by a score > 0 on the Non-Chemotherapy Anemia Symptom
             Scale [NCA-SS]).

        Exclusion Criteria:

          -  Had treatment with drugs or other agents targeting IL-6 or its receptor within 4 weeks
             of randomization.

          -  Any condition that, in the opinion of the investigator, would make participation not
             in the best interest (eg, compromise the well-being) of the patient or that could
             prevent, limit, or confound the protocol-specified assessments.

          -  Patients with Chronic Myelomonocytic Leukemia (CMML).

          -  Causes other than MDS contributing to anemia, such as Vitamin B12 or folate
             deficiency, bleeding, hemolysis, hemoglobinopathy, or chronic renal failure.
Clinical trial NCT01300013 (phase 2, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: placebo, omecamtiv mecarbil
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)N1CCN(CC2=C(F)C(NC(=O)NC3=CC=C(C)N=C3)=CC=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female 18 - 85 years

          -  Hospitalized for worsening heart failure, within 24 hours of initiating IV loop
             diuretic

          -  Dyspnea due to heart failure, at rest or with minimal exertion

          -  History of left ventricular ejection fraction (LVEF) ≤ 40%

          -  Elevated brain natriuretic peptide (BNP) or N-terminal fragment BNP (NT-proBNP)

        Exclusion Criteria:

          -  Receiving IV vasopressor (excluding low dopamine), inotropic or mechanical support

          -  Acute coronary syndrome (ACS)

          -  Within 30 days prior to enrollment: cardiac resynchronization therapy (CRT) or
             implantable cardioverter defibrillator (ICD) implantation, ACS, coronary
             revascularization, transient ischemic attack (TIA) or stroke, sustained ventricular
             arrhythmia, or major surgery

          -  Severe valvular stenosis, hypertrophic obstructive cardiomyopathy, active myocarditis,
             constrictive pericarditis, or clinically significant congenital heart disease

          -  Estimated glomerular filtration rate (eGFR) < 20 mL/min/1.73m2
Clinical trial NCT00694057 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: he3286, placebo
SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]2(O)C#C)[C@@H](O)C=C1C[C@@H](O)CC[C@]31C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Patient with a diagnosis of Type 2 Diabetes Mellitus (T2DM)

          -  Patient must be a) on a stable dose of metformin as monotherapy for at least 10 weeks
             prior to screening; or b) drug-naive, defined as never having received drug treatment
             for T2DM or not having received antidiabetic drug therapy during the 3 months prior to
             screening.

          -  Patient with a fasting blood glucose level of ≤ 225 mg/dL at screening (≤ 255 mg/dl
             for drug-naive patients);

          -  Patient with HbA1c levels >7.5% (7.0 - 10.5% for drug-naive patients) at screening;

          -  Patient with BMI 28-37 kg/m2 for females 28-39 kg/m2 for males

        Main Exclusion Criteria:

          -  Patient who has a history of clinically significant cardiovascular disease (including
             coronary artery disease), clinically significant hepatic, respiratory or renal
             abnormalities within 6 months prior to screening;

          -  Patient with unstable diabetic complications requiring treatment or ongoing active
             intervention;

          -  Patient with a history of long term insulin therapy within the past year;

          -  Patient who has had therapy with rosiglitazone, pioglitazone, exendin-4 or
             sitagliptin, alone or in combination within 6 months prior to screening;

          -  Patient who has any clinically significant abnormalities in laboratory results at
             screening;
Clinical trial NCT00413959 (phase 2, status: terminated)
Conditions: lymphoma, non-hodgkin, lymphoma, b-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: velcade®, rituximab, cyclophosphamide, decadron
SMILES: CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Small Lymphocytic Lymphoma

          -  Follicular Cell Lymphoma (grades I and II)

          -  Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy
             and stem cell transplant

          -  Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia

          -  Marginal Zone Lymphoma

          -  MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.

          -  Adequate bone marrow function, renal function, and hepatic function as outlined in
             details below.

          -  ECOG performance status of 0, 1, or 2

          -  Able to read, understand, and sign an IRB approved informed consent

        Exclusion Criteria:

          -  Known HIV positive status

          -  Known CNS involvement

          -  Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.
Clinical trial NCT00724009 (phase 2, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: clofarabine
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Capable of understanding the investigational nature, potential risks and benefits of
             the study, and able to provide valid informed consent.

          -  Adequate hepatobiliary function as indicated by the following laboratory values:

               -  SGOT/SGPT <=2.5 x upper limit of normal

               -  Alkaline phosphatase <=2.5 x upper limit of normal

               -  Serum bilirubin < 1.5 mg/dl

               -  Adequate renal function as indicated by the following laboratory values:

               -  Creatinine Clearance >50 ml/min

          -  Age >/=18 years

          -  Zebroid performance status </= 2 (See Appendix A)

          -  Life expectancy is not severely limited by concomitant illness (i.e. < 3months life
             expectancy from non-leukemic conditions).

          -  No evidence of chronic active hepatitis or cirrhosis.

          -  HIV-negative

          -  Male and female patients must use an effective contraceptive method during the study
             and for a minimum of 6 months after study treatment.

          -  Female patients of childbearing potential must have a negative serum pregnancy test
             within 2 weeks prior to enrollment.

        Exclusion Criteria:

          -  Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as
             specified in the protocol.

          -  Use of investigational agents within 30 days or any anticancer therapy within 2 weeks
             before study entry with the exception of hydroxyurea. The patient must have recovered
             from all acute non-hematologic toxicities from any previous .

          -  Have any other severe concurrent disease, or have a history of serious organ
             dysfunction or disease involving the heart, kidney, liver, or other organ system that
             may place the patient at undue risk to undergo treatment.

          -  Patients with a systemic fungal, bacterial, viral, or other infection not controlled
             (defined as exhibiting ongoing signs/symptoms related to the infection and without
             improvement, despite appropriate antibiotics or other treatment).

          -  Pregnant or lactating patients.

          -  Any significant concurrent disease, illness, or psychiatric disorder that would
             compromise patient safety or compliance, interfere with consent, study participation,
             follow up, or interpretation of study results.
Clinical trial NCT00135798 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: ladr treatment
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult (18 or older)

          -  LDLT candidate

          -  HCV RNA positive

          -  Expected time on treatment is at least 12 weeks

          -  Candidates for DDLT who are listed for transplantation and meet UNOS criteria for MELD
             upgrade for HCC

        Exclusion Criteria:

          -  Severe cytopenia (polymorphonuclear (PMN) leukocytes < 750, OR hemoglobin [Hgb] < 10
             g/dL, OR platelet count < 35,000/mm3)

          -  Uncontrolled depression or psychiatric disease characterized by current symptoms of
             major depression or other psychiatric disease or increase in medication for major
             depression or other psychiatric disease within the past three months.

          -  Uncontrolled cardiopulmonary disease characterized by myocardial infarction, coronary
             artery bypass graft surgery, Percutaneous coronary intervention, or unstable angina
             within the past three months.

          -  Uncontrolled autoimmune disease characterized by current symptoms of autoimmune
             disease or increase in medications within the last three months.

          -  Autoimmune hepatitis

          -  Active substance abuse within 6 months of initiation of treatment

          -  Known intolerance or serious adverse event during prior therapy with interferon or
             ribavirin

          -  Prior nonresponse after at least 24 weeks of full dose treatment with peginterferon
             plus ribavirin

          -  Laboratory Model for End-Stage Liver Disease (MELD) score >20. Patients with
             laboratory MELD score 21-25 may be enrolled if deemed appropriate by the site
             investigator

          -  Serum creatinine >2.2 mg/dL
Clinical trial NCT01072383 (phase 2, status: completed)
Conditions: psoriasis vulgaris
ICD codes: L40.0
Drugs: bt061, placebo treatment
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female patients with moderate, moderate to severe or severe chronic plaque
             psoriasis diagnosed ≥ 12 months prior to Screening.

          -  BSA (Body surface area) involvement > 10% for more than 6 months.

          -  PASI ≥10.

          -  Age ≥ 18 to ≤ 75 years.

          -  Body mass index (BMI) of 18-30 kg/m2 with a body weight between 50 and 130 kg.

        Exclusion Criteria:

          -  Erythrodermic, guttate or palmar pustular psoriasis (mixed forms may be admissible if
             chronic plaque psoriasis clearly remains the predominant diagnosis

          -  Treatment with a biological within less than 30 days or within less than 5 half-lives
             of the respective compound prior to administration of BT061/placebo.

          -  Serious local (e.g. abscess) or systemic infection (e.g. pneumonia, septicaemia)
             within 3 months prior to the administration of BT061 or placebo.

          -  Presence or history of clinically significant immune deficiency or autoimmune disease
             (except psoriasis).

          -  Positive diagnosis for acute or chronic infections (i.e. Hepatitis C Virus [HCV],
             Hepatitis B Virus [HBV], Human Immunodeficiency Virus [HIV]) at Screening visit.
Clinical trial NCT00268996 (phase 2, status: completed)
Conditions: atherosclerosis
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83
Drugs: sb-480848, sb-480848 matching placebo
SMILES: CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1, CCN(CC)CCN(CC1=CC=C(C=C1)C1=CC=C(C=C1)C(F)(F)F)C(=O)CN1C2=C(CCC2)C(=O)N=C1SCC1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Successful PCI (Percutaneous Coronary Intervention) or uncomplicated diagnostic
             catheterization

          -  Suitable non-intervened coronary artery with IVUS

          -  Antiplatelet therapy

        Exclusion criteria:

          -  Clinical instability

          -  Previous CABG (Coronary Artery By-pass Graft) surgery

          -  Planned major surgery

          -  Recent stroke

          -  Abnormal QTc

          -  Renal or hepatic impairment

          -  Uncontrolled hypertension

          -  Use of corticosteroids

          -  Class III or IV heart failure

          -  Asthma
Clinical trial NCT01161537 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-770, placebo
SMILES: CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female with Cystic Fibrosis

          -  Must have the G551D-CFTR mutation on at least 1 allele

          -  FEV1 ≥40% of predicted normal for age, gender, and height at Screening

          -  12 years of age or older

          -  Must be able to swallow tablets

        Exclusion Criteria:

          -  History of solid organ or hematological transplantation

          -  Ongoing participation in another therapeutic clinical study or prior participation in
             an investigational drug study within the 30 days prior to screening

          -  Use of inhaled hypertonic saline treatment within 14 days prior to the Screening Visit

          -  Extensive body tattoos or other physical features that will confound MRI
Clinical trial NCT00148720 (phase 2, status: terminated)
Conditions: invasive breast carcinoma, primary invasive breast cancer, stage i breast cancer, stage ii breast cancer, stage iii breast cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histological confirmation of primary invasive breast cancer

          -  Stage I-III operable breast cancer.

          -  Primary tumor must be greater than or equal to 2cm by radiographic imaging or
             palpitation

          -  Women greater than 18 years of age

          -  ECOG performance status 0-1

          -  WBC > 4000/mm3

          -  Platelet count > 100,000/mm3

          -  SGOT < 2x ULN

          -  Calculated creatinine clearance > 50ml/min

        Exclusion Criteria:

          -  Evidence of metastatic (stage IV) cancer on physical exam or any diagnostic study.

          -  Pregnant or breast-feeding women

          -  Inflammatory breast cancer

          -  HER2 positive disease

          -  History of hypersensitivity to a 5-FU or known dihydropyrimidine dehydrogenase (DPD)
             deficiency

          -  Uncontrolled intercurrent illness

          -  Prior history of breast cancer are ineligible except: diagnosed at least 2 years ago;
             present cancer is not in previously irradiated breast; no prior chemotherapy in the
             past 5 years; no prior high-dose chemotherapy with stem cell or bone marrow
             transplant.

          -  Excisional biopsy performed prior to enrollment

          -  Uncontrolled coagulopathy

          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption
             syndrome.
Clinical trial NCT01499303 (phase 2, status: completed)
Conditions: diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: fostamatinib
SMILES: COC1=CC(NC2=NC=C(F)C(NC3=CC=C4OC(C)(C)C(=O)NC4=N3)=N2)=CC(OC)=C1OC
Eligibility criteria:

        Inclusion Criteria:

          -  Aged at least 18 years of age.

          -  Patients with relapsed or refractory diffuse large B-cell lymphoma who have previously
             received R-CHOP (or equivalent) chemo-immunotherapy and high dose chemotherapy with
             stem cell rescue, or who are ineligible for high dose therapy with stem cell rescue.

          -  Measurable disease as defined by Cheson et al 2007 criteria.

          -  One fresh pre-treatment excisional or core needle biopsy from suitable and accessible
             site.

          -  World Health Organization (WHO) performance status 0 to 1.

        Exclusion Criteria:

          -  Treatment with nitrosurea, mitomycin C, investigational agents or study drugs w/in28
             days of first dose of study treatment, any other chemotherapy, immunotherapy or
             anticancer agents w/in 3 weeks of first dose of study treatment, previous
             fostamatinib.

          -  With the exception of alopecia, any unresolved toxicities from prior therapy or
             surgery greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1.

          -  Uncontrolled hypertension (defined as >140mmHg systolic and/or > 90 mmHG diastolic at
             baseline with or without antihypertensive therapy.

          -  Evidence of tuberculosis (TB).

          -  Inadequate boen marrow reserve.
Clinical trial NCT01204528 (phase 2/phase 3, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: zemplar
SMILES: [H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)O
Eligibility criteria:

        Inclusion Criteria:

        eGFR 15-59 ml/m2

        Exclusion Criteria:

        Current vitamin D treatment
Clinical trial NCT00832520 (phase 2, status: terminated)
Conditions: advanced cancer
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: remeron (mirtazapine)
SMILES: CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Reason stopped: 
    low accrual rate.
  
Eligibility criteria:

        Inclusion Criteria:

          1. All patients, 18 years of age or older, with advanced cancer are eligible.

          2. Patients must have lost 10% in the last 6 months

          3. Patients must have a life expectancy of at least 12 weeks.

          4. Patients must have a Zubrod performance status of 0-3.

          5. Patients must sign an informed consent.

        Exclusion Criteria:

          1. Patients with symptomatic brain metastases are excluded from this study.

          2. Pregnant women or nursing mothers are not eligible for this trial. Patients of child
             bearing potential must use adequate contraception.

          3. Patients with severe medical problems such as uncontrolled diabetes mellitus or
             cardiovascular disease or active infections are not eligible for this trial.

          4. Patients with head and neck cancers and GI cancers who have functional problems that
             limits food intake or absorption of nutrients such as partial or complete bowel
             obstructions, and patients with skin cancers (except melanoma) are not eligible

          5. Patients who lost weight on a voluntary diet.

          6. Patients who are already taking an appetite stimulant or other anti-depressant, except
             for SSRI taken in the morning.

          7. Patients who had surgery in the last 6 months